Maintain Buy: Cost Controls Effective, China Business Nearing Bottom

Overview

This report summarizes Goldman Sachs’ investor conference call on Sysmex held on May 27, 2026. The core conclusion is that while China’s standardized testing pricing policy will weigh on FY27 full-year profit expectations, strict cost controls enabled FY26 results to slightly exceed guidance. Meanwhile, robust growth in coagulation businesses in Europe and the U.S. and in emerging markets will partially offset China-related headwinds. The firm maintains a 'Buy' rating with a target price of JPY 1,700.

Core views

In terms of performance, Sysmex’s FY26 (ended March 2026) profit (excluding one-time items like impairments) slightly exceeded the revised Q3 guidance, primarily due to effective cost control measures. Although regional profitability in Q4 FY26 was slightly below company expectations (due to tender delays or shipment pauses in parts of Asia-Pacific and Europe), demand in China’s hematology business outperformed expectations, and the overall China business showed no further deterioration. Looking ahead to FY27, the company has adopted a more conservative stance, fully incorporating uncertainties around its China operations. Distributor inventory adjustments—driven by reagent shelf-life considerations—are expected to largely conclude in H1 FY27, clearing most prior negative impacts. However, H2 will face downward pressure on full-year profits due to the implementation of China’s standardized testing pricing. As a key variable in operating profit guidance, the company specifically highlighted the timing and details of China’s standardized pricing and the progress on U.S. tariff refunds (the latter not included in current guidance). On growth drivers, beyond stabilization in China, the firm emphasizes three key areas: (1) sales growth from new hematology products; (2) expansion of the coagulation business in Europe and the U.S., particularly driven by high-end models launched in Europe in FY26; and (3) sustained high growth in emerging markets such as India and Brazil. Additionally, the company plans to launch next-generation high-end instruments leveraging AI and proprietary data during its medium-term planning period, with initial rollout in Japan starting in FY27 and contributions to Europe and the U.S. expected in the subsequent cycle. Regarding profitability improvement, the company aims to optimize its product mix by increasing sales of higher-margin reagents and actively switching raw materials and sourcing channels to reduce cost of goods sold (COGS). Although SG&A expenses will rise in FY27 due to factors like the clinical chemistry business transition, the company commits to enhancing productivity through digitalization and other initiatives over the medium term.

Analysis framework

The report employs a ‘regional segmentation + key policy sensitivity analysis’ framework. First, global operations are segmented into China, Europe/U.S., and emerging markets for separate assessment: the China segment focuses on how centralized procurement policies transmit to pricing and demand, along with inventory cycles; the Europe/U.S. segment emphasizes incremental opportunities from product iteration (high-end models). Second, regarding China—a critical variable—the report avoids simplistic linear forecasts and instead introduces ‘standardized testing pricing’ as a pivotal external factor, analyzing its asymmetric impact across fiscal halves (H1 vs. H2), reflecting granular tracking of policy implementation timing. Finally, combining dual logic from the cost side (COGS optimization) and revenue side (product mix upgrade), the report concludes that the company can sustain long-term profitability even amid revenue pressure.

Methodology notes

• Industry/Industrial Analysis FrameworkUpstream-Midstream-Downstream Industry Chain Transmission

  Relationship between distributor inventory adjustments and end-market demand

  The report analyzes distributors’ inventory levels and product shelf life (e.g., ~1 year for hematology reagents) to infer the endpoint of industry destocking cycles, thereby gauging when demand may rebound—a classic supply chain transmission analysis.

• Valuation MethodEV/EBITDA valuation

  Multiple discounting in relative valuation

  The report uses the average EV/EBITDA multiple of the global medical device sector (11.0x) as an anchor and applies a 20% discount to derive the target price, accounting for stock-specific risk premiums or differences in growth quality versus the sector average.

• Company Fundamentals & Financial FrameworkFree cash flow analysis

  Cost structure and margin improvement pathway

  The report dissects drivers behind changes in COGS and SG&A (e.g., raw material substitution, digital efficiency gains) to analyze how the company can restore margins through internal operational improvements despite slowing revenue growth.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sysmex (6869.T)

  Direct coverage target, benefiting from global hematology and coagulation business recovery and cost control

  Strengths

  Global leadership position, broad product portfolio, competitive advantage in high-end coagulation markets in Europe and the U.S., strong cost control capabilities

  Weaknesses

  China business temporarily pressured by standardized testing pricing policy, FY27 profit under pressure

  Comparison

  Higher technological barriers compared to domestic players; greater focus in specific segments (e.g., hematology) compared to other multinational IVD giants

  Risks

  China centralized procurement policy more aggressive than expected, geopolitical risks, currency fluctuations

Key data

• Current Share PriceJPY 1,397Closing price as of May 29, 2026
• 12-Month Target PriceJPY 1,700Based on FY28E EV/EBITDA of 11.0x with a 20% discount
• Implied Upside21.7%Calculated based on current price and target price
• FY26 Revenue ForecastJPY 500 billionCompany data and Goldman Sachs estimates
• FY27 Operating Profit ForecastJPY 60.1 billionYear-over-year increase, though full-year FY27 profit impacted by China pricing policy
• FY26 Earnings Per Share (EPS)JPY 56.9Actual figure
• FY27 Earnings Per Share (EPS) ForecastJPY 60.5Modest year-over-year increase

Impact & implications

For Chinese investors, this report highlights the tangible near-term earnings impact of domestic consumables centralized procurement policies on overseas equipment manufacturers, while also demonstrating that leading companies possess the capability—through product mix optimization and cost control—to navigate cyclical pressures. For global allocators, growth in Europe/U.S. coagulation businesses and sustained momentum in emerging markets offer effective hedges against single-market risk. In the long run, AI-enabled premium devices will become a new competitive frontier in the industry, potentially reshaping valuation frameworks.

Risks

• Geopolitical risks and supply chain shifts
• Global healthcare system reforms and cost-containment policies
• Intensifying competition (especially price erosion from rising local players in emerging markets)
• Currency fluctuations
• Heightened inflationary pressures
• Weakening capital expenditure trends

What to watch

• Specific implementation details and timeline of China’s standardized testing pricing policy
• Progress on U.S. tariff refund developments
• Launch of next-generation AI-powered flagship instruments and their contribution to overseas markets
• Whether distributor inventory adjustments conclude as expected in H1 FY27
• Effectiveness of gross margin improvement initiatives